PL1720531T3 - Nowe kompozycje zawierające związki chinoliny - Google Patents

Nowe kompozycje zawierające związki chinoliny

Info

Publication number
PL1720531T3
PL1720531T3 PL05707942T PL05707942T PL1720531T3 PL 1720531 T3 PL1720531 T3 PL 1720531T3 PL 05707942 T PL05707942 T PL 05707942T PL 05707942 T PL05707942 T PL 05707942T PL 1720531 T3 PL1720531 T3 PL 1720531T3
Authority
PL
Poland
Prior art keywords
compositions containing
new compositions
quinoline compounds
containing quinoline
compounds
Prior art date
Application number
PL05707942T
Other languages
English (en)
Inventor
Karl Jansson
Tomas Fristedt
Hans WÄNNMAN
Anders Björk
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of PL1720531T3 publication Critical patent/PL1720531T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL05707942T 2004-02-06 2005-02-04 Nowe kompozycje zawierające związki chinoliny PL1720531T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0400235A SE0400235D0 (sv) 2004-02-06 2004-02-06 New composition containing quinoline compounds
EP05707942A EP1720531B1 (en) 2004-02-06 2005-02-04 New compositions containing quinoline compounds
PCT/EP2005/050485 WO2005074899A2 (en) 2004-02-06 2005-02-04 New compositions containing quinoline compounds

Publications (1)

Publication Number Publication Date
PL1720531T3 true PL1720531T3 (pl) 2011-09-30

Family

ID=31885235

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05707942T PL1720531T3 (pl) 2004-02-06 2005-02-04 Nowe kompozycje zawierające związki chinoliny

Country Status (25)

Country Link
US (1) US7589208B2 (pl)
EP (1) EP1720531B1 (pl)
JP (1) JP4864724B2 (pl)
KR (3) KR20120062029A (pl)
CN (1) CN1980669B (pl)
AP (1) AP2395A (pl)
AT (1) ATE505186T1 (pl)
AU (1) AU2005210174B2 (pl)
BR (1) BRPI0506906B1 (pl)
CA (1) CA2552463C (pl)
CY (1) CY1111697T1 (pl)
DE (1) DE602005027445D1 (pl)
DK (1) DK1720531T3 (pl)
ES (1) ES2364754T3 (pl)
IL (1) IL176255A (pl)
NO (1) NO337235B1 (pl)
NZ (1) NZ548469A (pl)
PL (1) PL1720531T3 (pl)
PT (1) PT1720531E (pl)
RU (1) RU2339622C2 (pl)
SE (1) SE0400235D0 (pl)
SI (1) SI1720531T1 (pl)
UA (1) UA90463C2 (pl)
WO (1) WO2005074899A2 (pl)
ZA (1) ZA200605619B (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
BRPI0617477A2 (pt) * 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
AU2016219571B2 (en) * 2005-12-28 2018-03-15 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2013201426B2 (en) * 2005-12-28 2016-06-02 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CN101466379B (zh) 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
KR20100097145A (ko) * 2007-11-27 2010-09-02 오하라 야꾸힝 고교 가부시키가이샤 조립물의 제조 방법
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8354428B2 (en) * 2008-07-01 2013-01-15 Actavis Group Ptc Ehf Solid state forms of laquinimod and its sodium salt
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2009288108B2 (en) * 2008-09-03 2013-10-17 Teva Pharmaceutical Industries, Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
NZ623273A (en) * 2008-12-05 2015-09-25 Abraxis Bioscience Llc Sparc binding scfvs
DE102008064379A1 (de) * 2008-12-22 2010-07-15 Siemens Aktiengesellschaft Magnetspulenanordnung mit festen und beweglichen Spulen
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
JP5503192B2 (ja) * 2009-06-03 2014-05-28 大原薬品工業株式会社 生理活性物質含有粒子の製造方法
NZ597378A (en) 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
BR112012002124A2 (pt) * 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
WO2011086470A1 (en) 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
US20120022102A1 (en) * 2010-01-20 2012-01-26 Cadila Healthcare Limited Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof
KR20130006640A (ko) 2010-03-03 2013-01-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
US20110217295A1 (en) * 2010-03-03 2011-09-08 Asi Haviv Treatment of lupus arthritis using laquinimod
EA201290860A1 (ru) 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
AU2011231710B2 (en) * 2010-03-23 2013-07-25 Vifor (International) Ag Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
AU2011274496B2 (en) * 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
JP5934202B2 (ja) * 2010-07-09 2016-06-15 テバ ファーマシューティカル インダストリーズ リミティド ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用
KR20130065728A (ko) 2010-10-14 2013-06-19 임뮤나르 에이비 Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
AR086606A1 (es) 2011-05-31 2014-01-08 Vifor Int Ag Compuestos del complejo de fe(iii) para el tratamiento y profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) * 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
RU2641030C2 (ru) * 2012-12-21 2018-01-15 Вифор (Интернациональ) Аг Комплексные соединения трехвалентного железа для лечения и профилактики симптомов дефицита железа и железодефицитных анемий
WO2014152009A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
JP2016514162A (ja) 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
EP3041472B1 (en) 2014-09-23 2017-02-01 Active Biotech AB Quinoline carboxamides for use in the treatment of multiple myeloma
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
BR112017009854B1 (pt) 2014-11-19 2022-08-23 Active Biotech Ab Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
KR20180065223A (ko) 2016-12-07 2018-06-18 순천향대학교 산학협력단 천식의 치료 또는 완화용 약학 조성물
BR112021001984A2 (pt) 2018-08-15 2021-05-11 Pharmacyl Ab composto, combinação, composição farmacêutica, conjunto de partes, uso de composto, e, método para tratamento de uma doença resultante de inflamação patológica
KR102954667B1 (ko) 2018-08-15 2026-04-17 파마실 아베 치환된 벤즈아미드 및 치료법에서 이의 용도
JP2023527782A (ja) * 2020-05-21 2023-06-30 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びその使用
US20230293512A1 (en) 2020-07-23 2023-09-21 Erasmus University Medical Center Rotterdam S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
WO2022152902A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5077851A (en) * 1989-02-27 1992-01-07 Guma Juan M Method and apparatus for treating corded fabrics
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
DK0814782T3 (da) * 1995-12-22 2002-12-16 Nissan Chemical Ind Ltd Farmaceutisk præparat stabiliseret med et basisk middel
US5965560A (en) * 1996-04-30 1999-10-12 Warner-Lambert Company Substituted piperazines and piperidines as central nervous system agents
CN1264837C (zh) * 1997-09-15 2006-07-19 普罗克特和甘保尔公司 喹诺酮抗微生物剂、其组合物和应用
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives

Also Published As

Publication number Publication date
JP4864724B2 (ja) 2012-02-01
UA90463C2 (ru) 2010-05-11
WO2005074899A3 (en) 2007-04-19
KR101189557B1 (ko) 2012-10-12
EP1720531A2 (en) 2006-11-15
CA2552463C (en) 2013-05-14
WO2005074899A2 (en) 2005-08-18
KR20120062029A (ko) 2012-06-13
IL176255A (en) 2011-11-30
KR101457463B1 (ko) 2014-11-04
AU2005210174B2 (en) 2010-10-07
NZ548469A (en) 2010-05-28
PT1720531E (pt) 2011-06-27
ZA200605619B (en) 2007-11-28
ATE505186T1 (de) 2011-04-15
CN1980669B (zh) 2011-11-30
RU2339622C2 (ru) 2008-11-27
SI1720531T1 (sl) 2011-08-31
US7589208B2 (en) 2009-09-15
AP2395A (en) 2012-04-10
DK1720531T3 (da) 2011-08-01
HK1105866A1 (en) 2008-02-29
CN1980669A (zh) 2007-06-13
KR20060130191A (ko) 2006-12-18
EP1720531B1 (en) 2011-04-13
SE0400235D0 (sv) 2004-02-06
KR20130012084A (ko) 2013-01-31
CA2552463A1 (en) 2005-08-18
NO20063931L (no) 2006-09-04
ES2364754T3 (es) 2011-09-13
JP2007520529A (ja) 2007-07-26
RU2006132070A (ru) 2008-03-20
BRPI0506906B1 (pt) 2018-05-15
DE602005027445D1 (de) 2011-05-26
IL176255A0 (en) 2006-10-05
US20050192315A1 (en) 2005-09-01
AP2006003674A0 (en) 2006-08-31
AU2005210174A1 (en) 2005-08-18
CY1111697T1 (el) 2015-10-07
BRPI0506906A (pt) 2007-05-29
NO337235B1 (no) 2016-02-15

Similar Documents

Publication Publication Date Title
IL176255A0 (en) New compositions containing quinoline compounds
IL208963A0 (en) Substituted quinoline compounds
ZA200904425B (en) Nemathical compositions
EP1718714A4 (en) COMPOSITIONS CONTAINING A PLOTTER
EP1718638A4 (en) NEW COMPOUNDS
IL182126A0 (en) Compositions containing 5-phenoxyalkoxypsoralen derivatives
IL190321A0 (en) Compositions containing saratin
GB0405406D0 (en) Anti-vaginitis compositions
EP1805132A4 (en) NEW COMPOUNDS
GB0427403D0 (en) Novel compounds I
EP1796793A4 (en) NEW CONNECTIONS
ZA200701197B (en) Compositions
GB0410140D0 (en) Compositions
GB0402355D0 (en) Novel compounds
GB0402356D0 (en) Novel compounds
ZA200605575B (en) Substituted quinoline compounds
GB0425445D0 (en) Novel compositions
GB0420627D0 (en) Monoglyceride-containing compositions
GB0519969D0 (en) Quinoline compounds
GB0428061D0 (en) Novel Quinoline Compounds
GB0417193D0 (en) Novel compositions
GB0417860D0 (en) Compositions
GB0401515D0 (en) Compositions
GB0407814D0 (en) Compositions
GB0407815D0 (en) Compositions